Olema Pharmaceuticals saw the highest growth of 1.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Olema Pharmaceuticals‘s patent filings and grants. Buy the databook here.
Olema Pharmaceuticals has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with five publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 71% of filings. The World Intellectual Property Organization(WIPO), European Patent Office(EPO), United States(US), and Israel(IL) patent Office are among the top ten patent offices where Olema Pharmaceuticals is filings its patents. Among the top granted patent authorities, Olema Pharmaceuticals has 100% of its grants in Israel(IL).
Roche and Johnson & Johnson could be the strongest competitors for Olema Pharmaceuticals
Patents related to rare diseases lead Olema Pharmaceuticals's portfolio
Olema Pharmaceuticals has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Breast cancer related patents lead Olema Pharmaceuticals portfolio followed by ovarian cancer, and lung cancer
Olema Pharmaceuticals has highest number of patents in breast cancer followed by ovarian cancer, lung cancer, bone cancer, and uterine cancer. For breast cancer, nearly 12% of patents were filed and 50% of patents were granted in Q2 2024.
For comprehensive analysis of Olema Pharmaceuticals's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.